A Phase II Open Label, Multicenter, Trial of JNJ-42756493 In Combination With Dexamethasone For The Treatment Of FGFR3 Wild-type Or Mutation Positive Relapsed and/or Refractory Multiple Myeloma
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Dexamethasone (Primary) ; Erdafitinib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 15 Sep 2020 Status changed from recruiting to discontinued.
- 13 Dec 2019 Planned End Date changed from 1 Dec 2023 to 1 Dec 2020.
- 13 Dec 2019 Planned primary completion date changed from 1 Jan 2023 to 1 Dec 2020.